[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![whispertickers Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1937935302200373248.png) WhisperTick [@whispertickers](/creator/twitter/whispertickers) on x XXX followers
Created: 2025-07-27 08:15:56 UTC

Cash burning, pipeline swelling. But is anyone still listening to $MRNA?

Revenue shrinkage: guidance for 2025 just $1.5–2.5bn. Down XX% from pandemic peaks. Not a typo.

• Cost-cutting: $1bn off the table for next year.
• Pipeline? Forty-five programmes, nine in phase X. Ambitious, if you like optionality with your quarterly losses.
• Share price: $XX. Down XX% in twelve months. That’s one way to reprice risk.
• DCF says $50–65 is “fair”. But only if the dominoes fall.

Meanwhile, new COVID, RSV and oncology shots inch forward as the street eyes cash burn and market patience thinning by the quarter. Still too early for a eulogy—unless Q2 brings a surprise.

Full breakdown, warts and all:

Still confident, or just stubborn?


XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949383238830432457/c:line.svg)

**Related Topics**
[if you](/topic/if-you)
[$1bn](/topic/$1bn)
[$1525bn](/topic/$1525bn)
[$mrna](/topic/$mrna)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/whispertickers/status/1949383238830432457)